by smcork | Oct 11, 2012 | Commentary
When the Supreme Court upheld the constitutionality of the Patient Protection and Affordable Care Act on June 28, the impact was diverse and widespread. Relief was felt in one corner of the pharmaceutical industry, however, as the decision protected continued...
by Liza Roe | Dec 17, 2011 | Commentary
This summer, the FDA issued a draft guidance document addressing how the agency intends to apply its regulatory authority to Mobile Medical Applications (MMAs). The guidance document defines mobile applications as “software applications that can be executed (run) on a...
by prewittm | Sep 21, 2011 | Commentary
Lionel Messi is perhaps the world’s most celebrated soccer player. Despite standing only 5’6”, the Argentinian striker is strong, fast, and impossibly skilled. However, as a child, doctors predicted he wouldn’t grow any taller than 4’7”. Diagnosed at age 11 with a...
by emajchrz | Oct 31, 2010 | Cases
On October 6, 2010, the Federal Circuit released a decision holding that unenforceable patents can be the cause of a justiciable controversy under Article III of the United States Constitution if the patents block a generic pharmaceutical manufacturer’s entry into the...
by seidmand | Oct 30, 2010 | Commentary
In the wake of the HITECH Act, which encourages healthcare providers to use Electronic Health Records (EHR) through subsidies and reduced Medicare payments, patients may know that providers routinely store and transmit electronically their personal health-related...
